Manley Harold J, Grabe Darren W
School of Pharmacy, University of Missouri-Kansas City, Kansas City, Missouri, USA.
BMC Nephrol. 2004 Jan 12;5:1. doi: 10.1186/1471-2369-5-1.
Intravenous iron is typically administered during the hemodialysis (HD) procedure. HD patients may be prescribed high-flux (HF) or high-efficiency (HE) dialysis membranes. The extent of iron sucrose and iron dextran removal by HD using HF or HE membranes and by ultrafiltration rate (UFR) is unknown.
Two in vitro HD systems were designed and constructed to determine the dialyzabiltiy of iron from a simulated blood system (SBS) containing 100 mg iron sucrose or iron dextran (system A) or 1000 mg iron sucrose (system B). Both in vitro systems utilized a 6-L closed-loop SBS system that was subject to 4 different HD conditions conducted over 4 hours: HE membrane + 0 ml/hr UFR; HE membrane + 500 ml/hr UFR; HF membrane + 0 ml/hr UFR; HF membrane + 500 ml/hr UFR. Blood flow and dialysate flow rates were 500 ml/min and 800 ml/min, respectively. The dialysate compartment was a 192-L open system for system A and a 6-L closed-loop system for system B. Samples from the SBS and dialysate compartments were taken at various time points and iron elimination rate and HD clearance was determined. Iron removal from the SBS > 15% was considered clinically significant.
The greatest percentage removal from the SBS was 13.5% and -0.03% utilizing system A and B, respectively. Iron sucrose and iron dextran dialysate concentration was below the lower limits of assay (< 2 ppm) for system A. Dialysate recovery of iron was negligible: 0-5.4 mg system A and 5.47-23.59 mg for system B. Dialyzer type or UFR did not affect iron removal.
HF or HE dialysis membranes do not remove clinically significant amounts of iron sucrose or dextran formulations over a 4-hour HD session. This effect remained constant even controlling for UFR up to 500 ml/hour. Therefore, iron sucrose and iron dextran are not dialyzed by HE or HF dialysis membranes irrespective of UFR.
静脉铁剂通常在血液透析(HD)过程中给药。HD患者可能会被开具高通量(HF)或高效(HE)透析膜。使用HF或HE膜以及超滤率(UFR)进行HD时,蔗糖铁和右旋糖酐铁的清除程度尚不清楚。
设计并构建了两个体外HD系统,以确定含有100mg蔗糖铁或右旋糖酐铁的模拟血液系统(SBS)(系统A)或1000mg蔗糖铁(系统B)中铁的透析性。两个体外系统均使用6L闭环SBS系统,该系统在4小时内接受4种不同的HD条件:HE膜+0ml/hr UFR;HE膜+500ml/hr UFR;HF膜+0ml/hr UFR;HF膜+500ml/hr UFR。血流速率和透析液流速分别为500ml/min和800ml/min。系统A的透析液腔室为192L开放系统,系统B的透析液腔室为6L闭环系统。在不同时间点采集SBS和透析液腔室的样本,并测定铁清除率和HD清除率。SBS中铁清除率>15%被认为具有临床意义。
系统A和系统B从SBS中最大清除百分比分别为13.5%和-0.03%。系统A中蔗糖铁和右旋糖酐铁的透析液浓度低于检测下限(<2ppm)。透析液中铁的回收率可忽略不计:系统A为0-5.4mg,系统B为5.47-23.59mg。透析器类型或UFR不影响铁的清除。
在4小时的HD疗程中,HF或HE透析膜不会清除具有临床意义量的蔗糖铁或右旋糖酐制剂。即使将UFR控制在高达500ml/小时,这种效果仍保持不变。因此,无论UFR如何,蔗糖铁和右旋糖酐铁都不会被HE或HF透析膜透析。